These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33687148)

  • 1. The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.
    Chan PLS; McFadyen L; Quaye A; Leister-Tebbe H; Hendrick VM; Hammond J; Raber S
    CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):551-563. PubMed ID: 33687148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion.
    Riccobene TA; Carrothers TJ; Knebel W; Raber S; Chan PLS
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):420-427. PubMed ID: 33465279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.
    Das S; Li J; Iaconis J; Zhou D; Stone GG; Yan JL; Melnick D
    J Antimicrob Chemother; 2019 Feb; 74(2):425-431. PubMed ID: 30380060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
    Riccobene TA; Khariton T; Knebel W; Das S; Li J; Jandourek A; Carrothers TJ; Bradley JS
    J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models.
    Cristinacce A; Wright JG; Macpherson M; Iaconis J; Das S
    Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115292. PubMed ID: 33360809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.
    Van Wart SA; Ambrose PG; Rubino CM; Khariton T; Riccobene TA; Friedland HD; Critchley IA; Bhavnani SM
    Antimicrob Agents Chemother; 2014; 58(2):885-91. PubMed ID: 24277021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil.
    Li J; Das S; Zhou D; Al-Huniti N
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):682-694. PubMed ID: 31044546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
    Drusano GL
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv33-9. PubMed ID: 21115453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
    Canut A; Isla A; Rodríguez-Gascón A
    Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil.
    Matzneller P; Lackner E; Lagler H; Wulkersdorfer B; Österreicher Z; Zeitlinger M
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3617-25. PubMed ID: 27044549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis.
    Riccobene T; Jakate A; Rank D
    J Clin Pharmacol; 2014 Jul; 54(7):742-52. PubMed ID: 24431097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftaroline Dosage Optimized for Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling.
    Zhou J; You X; Guo G; Ke M; Xu J; Ye L; Wu W; Huang P; Lin C
    J Clin Pharmacol; 2021 Dec; 61(12):1646-1656. PubMed ID: 34329494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials.
    Corey GR; Wilcox MH; Gonzalez J; Jandourek A; Wilson DJ; Friedland HD; Das S; Iaconis J; Dryden M
    Int J Antimicrob Agents; 2019 Jun; 53(6):830-837. PubMed ID: 30716446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h.
    Cheng K; Pypstra R; Yan JL; Hammond J
    J Antimicrob Chemother; 2019 Apr; 74(4):1086-1091. PubMed ID: 30597021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the pharmacokinetics and safety of single and multiple ceftaroline fosamil infusions in healthy Chinese and Western subjects.
    Yang L; Sunzel M; Xu P; Edeki T; Wilson D; Li J; Li H
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):681-91. PubMed ID: 26152131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
    Biek D; Critchley IA; Riccobene TA; Thye DA
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Noel AR; Tomaselli S; Bowker KE
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2451-6. PubMed ID: 23459495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Corrado ML
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis.
    Autry EB; Rybak JM; Leung NR; Gardner BM; Burgess DR; Anstead MI; Kuhn RJ
    Pharmacotherapy; 2016 Jan; 36(1):13-8. PubMed ID: 26748559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
    Van Wart SA; Forrest A; Khariton T; Rubino CM; Bhavnani SM; Reynolds DK; Riccobene T; Ambrose PG
    J Clin Pharmacol; 2013 Nov; 53(11):1155-67. PubMed ID: 23907740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.